Last updated: February 27, 2026
What is the Drug and its Market Position?
NDC 16714-0497 corresponds to Imlygic (talimogene laherparepvec), approved by the FDA in October 2015. It is an oncolytic virus therapy indicated for the treatment of melanoma lesions in patients with recurrent melanoma who are injectable and medically eligible.
Imlygic's mechanism involves selectively infecting and killing cancer cells while inducing an immune response. It represents a niche but growing segment involving oncolytic virus therapies.
Current Market Dynamics
Market Size and Usage
Imlygic's sales have been limited compared to standard melanoma treatments, such as immune checkpoint inhibitors. As of 2022, the drug generated approximately $27 million in U.S. sales, far below the blockbuster threshold. Key factors include:
- Patient eligibility: Only injectable melanoma lesions suitable for virus therapy.
- Competition: Immune checkpoint inhibitors (nivolumab, pembrolizumab) dominate melanoma treatment.
- Pricing: Current wholesale acquisition cost (WAC) per treatment cycle is roughly $65,000–$70,000.
Competitive Landscape
| Drug |
Type |
Approval Year |
Key Indications |
Market Share (est.) |
| Imlygic |
Oncolytic virus |
2015 |
Melanoma |
Low (approx. 5-10%) |
| Nivolumab |
PD-1 inhibitor |
2014 |
Melanoma, others |
High (over 50%) |
| Pembrolizumab |
PD-1 inhibitor |
2014 |
Melanoma, others |
High |
Distribution and Prescriber Trends
Physicians favor immune checkpoint inhibitors for advanced melanoma due to demonstrated survival benefits. Oncolytic virus therapy remains a secondary option, primarily for localized or injectable lesions.
Price Projections and Revenue Outlook
Factors Influencing Price and Sales
- Regulatory developments: Expansion of indications could increase eligible patient populations.
- Competitive pricing: Discounting or value-based pricing models could occur as more therapies enter the market.
- Manufacturing costs: The biological nature of Imlygic entails relatively high production costs, constraining downward price adjustments.
Short-term Price Trajectory (Next 1-3 Years)
| Scenario |
Price Range per Treatment Cycle |
Sales Volume |
Revenue Estimate (USD millions) |
| Conservative |
$65,000 |
2,000 cycles |
$130 million |
| Moderate |
$55,000 |
3,000 cycles |
$165 million |
| Aggressive discounting |
$45,000 |
4,000 cycles |
$180 million |
The price per cycle is anticipated to stabilize around $45,000–$65,000, with sales volume depending on broader adoption or regulatory expansion.
Long-term Outlook (3-5 Years)
- Market expansion: Pending approval for additional indications (e.g., for earlier-stage melanoma) could increase sales volume.
- Pricing pressures: As more oncolytic or immunotherapy options emerge, price competition could lower the price further, potentially to below $45,000 per cycle.
- Biosimilar threat: Incipient biosimilar products are unlikely in the near term due to the biological complexity.
Regulatory and Policy Impact
- The FDA has notified that Imlygic is eligible for expanded use in combination therapies.
- CMS and private payers may impose value-based rebates or coverage restrictions if cost-effectiveness is not demonstrated.
Summary of Key Data
- FDA approval date: October 2015
- Indication: Melanoma with injectable lesions
- 2019-2022 sales: $20–$30 million annually
- Pricing: $65,000–$70,000 per cycle
- Market share: 5–10% among melanoma therapies
Limitations and Risks
- The product's niche positioning limits growth.
- Competition from immunotherapies continues to increase.
- Reimbursement policies could pressure net prices.
- Technological advances in systemic therapies may diminish demand.
Key Takeaways
- Imlygic has a constrained market dominated by immune checkpoint inhibitors.
- Short-term prices are expected to remain near current levels but could decline with increased competition.
- Expansion of indications offers the best growth potential, contingent on regulatory approval.
- Market share is unlikely to increase significantly without a major therapeutic innovation.
FAQs
1. What are the primary factors influencing Imlygic's price?
Manufacturing costs, competitive landscape, regulatory approval for new indications, and payer negotiations influence pricing.
2. How does Imlygic compare price-wise to other melanoma treatments?
It costs approximately $65,000–$70,000 per cycle, comparable to initial immune checkpoint inhibitor costs but less effective overall, limiting its adoption.
3. What is Imlygic’s long-term revenue potential?
Limited unless expanded indications or combination therapies are approved; meanwhile, prices may decline under market pressures.
4. How does the competition from immune checkpoint inhibitors affect Imlygic?
It reduces demand due to superior efficacy, safety, and broader application of antibodies.
5. Are biosimilars or generics likely to impact Imlygic?
Biological complexity delays biosimilar entry; significant impact unlikely within the next 5 years.
References
[1] Food and Drug Administration. (2015). Imlygic (talimogene laherparepvec) approval.
[2] IQVIA. (2022). U.S. pharmaceutical sales data.
[3] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for melanoma therapies.
